Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesTransplantCentene allogeneic HCT Coverage Update | OpenPayer
    Ask Trek AI about this page
    ModifiedCentenePolicy CPMP.108

    Allogeneic Hematopoietic Cell Transplants for Sickle Cell Anemia and B-Thalassemia

    Customize your policy alerts

    Sign up for Centene Policy CPMP.108 alerts

    Get alerted when Policy CPMP.108 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Medical necessity criteria and coverage stance for allogeneic hematopoietic cell transplantation (HCT) to treat sickle cell anemia and homozygous B-thalassemia for Centene-affiliated health plans; intended for clinicians and prior authorization staff.

    Policy Summary
    PayerCentene
    PolicyAllogeneic Hematopoietic Cell Transplants for Sickle Cell Anemia and B-Thalassemia
    Policy CodePolicy CPMP.108
    Change TypeRevised criteria languageadded cross-references
    Effective Date
    Next Review Date
    Key ActionObtain prior authorization and supply documentation showing medical necessity criteria (donor/source, conditioning regimen, transfusion dependence, and absence of contraindications) are met.
    SourceLink
    POLICY UPDATE CHANGES

    Removed age limit criteria related to high risk of stroke and removed first-degree relative donor requirement for cord blood as the source of stem cells.

    Added notes referencing related products (Zynteglo and Casgevy) and Medicare-specific criteria reference.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    85–90%reported HCT success rate in specific pediatric groups
    65–90%reported overall and thalassemia-free survival range
    1,200patients reported (surveyed datasets)
    38205,38240,S2150example procedure codes
    19+bibliographic references cited

    Coverage Criteria

    Initial transplant coverage criteria

    Covered when ALL of the following are met for specific indications:

    Overall requirement: Allogeneic hematopoietic cell transplant (HCT) is medically necessary when disease-specific criteria for sickle cell anemia OR homozygous B-thalassemia are met, a standard myeloablative conditioning regimen will be used (where specified), and there are no absolute contraindications.

    See indication-specific nodes below.

    Indication selection: One of the following indications must apply: sickle cell anemia meeting the specified criteria OR homozygous B-thalassemia meeting the specified criteria.
    Sickle cell anemia criteria: Member has sickle cell anemia AND meets all of the following: history of stroke or is at high risk of stroke or end-organ damage demonstrated by at least one of: prior stroke, recurrent acute chest syndrome, recurrent vaso-occlusive crises, or red blood cell alloimmunization on chronic transfusion therapy; an appropriate HLA-matched donor is available; and the member does not have any absolute contraindications (including inability to adhere to post-transplant regimen, uncontrolled infection with highly virulent/resistant microbes, or active substance use/dependence without evidence of risk-reduction behaviors unless urgent timelines warrant conditional acceptance).

    Policy language was revised to remove a prior age limit for high stroke risk; younger recipients generally have better outcomes.

    Homozygous B-thalassemia criteria: Member has transfusion-dependent homozygous B-thalassemia AND meets all of the following: an appropriate HLA-matched donor is available; stem cell source is cord blood, bone marrow, or peripheral blood (peripheral blood acceptable when donor is unable or refuses to donate marrow); a standard myeloablative conditioning regimen will be used; and the member does not have any absolute contraindications (including inability to adhere to necessary regimen or uncontrolled virulent/resistant infections).

    Requirement that cord blood donor be a first-degree relative was removed in the latest revision.

    Autologous hematopoietic cell transplant (AHCT) for sickle cell anemia performed outside the context of gene therapy is considered to have insufficient evidence regarding safety and efficacy and is not covered under this policy.

    Allogeneic hematopoietic cell transplant (allo-HCT) for sickle cell anemia or homozygous B-thalassemia when requested for indications other than those explicitly specified in this policy are considered unsupported by the available evidence and risk denial.

    When state Medicaid coverage provisions conflict with this clinical policy, the state Medicaid provisions take precedence. Providers and reviewers should follow the applicable state Medicaid manual and any state-specific coverage rules in place for these services.

    Autologous hematopoietic cell transplant (AHCT) for B-thalassemia performed outside the context of gene therapy is considered to have insufficient evidence regarding safety and efficacy and is not medically necessary under this policy. This same determination applies to AHCT for sickle cell anemia when not part of a gene therapy approach.

    Coding and Related Metrics

    Referenced CPT codesCPT
    38205Blood-derived hematopoietic progenitor cell harvesting for transplantation, per collection; allogeneic.
    38240Hematopoietic progenitor cell (HPC); allogeneic transplantation per donor.
    Referenced HCPCS codesHCPCS
    S2150Bone marrow or blood-derived stem cells (peripheral or umbilical), allogeneic or autologous, harvesting, transplantation, and related complications; including: pheresis and cell preparation/storage; marrow ablative therapy; drugs, supplies, hospitalization with outpatient follow-up; medical/surgical, diagnostic, emergency, and rehabilitative services; and the number of days of pre- and posttransplant care in the global definition.
    Key outcomes — pediatric and overall
    Reported pediatric HCT success rate85–90% success rate reported for specific pediatric groups
    Three-year survival (surveyed datasets)Approximately 90% three‑year survival regardless of stem cell source
    Overall and thalassemia‑free survival rangeReported range approximately 65–90% across multiple reports

    Provider Actions and Requirements

    Prior Authorization

    Prior authorization required for listed transplant procedure codes

    Prior authorization is required for claims using the referenced transplant procedure codes; providers must supply documentation demonstrating that the authorization criteria are met when submitting claims for CPT 38205, CPT 38240, or HCPCS S2150.

    • Applicable procedure codes: 38205, 38240, S2150
    • Submit supporting documentation showing medical necessity per policy criteria
    Prior Authorization

    Confirm applicability of prior authorization with state/Medicare rules

    Determine whether prior authorization applies per this clinical policy and in accordance with applicable state Medicaid or Medicare coverage determinations before proceeding.

    • Review state Medicaid manual if member is enrolled in Medicaid
    • Review Medicare NCDs, LCDs, and Coverage Articles for Medicare members

    Candidate Selection Criteria

    Candidate selection

    Candidate requirements described in policy criteria sections for each disease:

    General candidate: Candidate must meet the disease-specific medical necessity criteria for the selected indication (sickle cell anemia or homozygous B-thalassemia), have an appropriate donor/source available per the indication, and have no absolute contraindications to transplant.

    Absolute contraindications include inability to adhere to the required regimen even with caregiver support; uncontrolled infections with highly virulent or resistant microbes that are poorly controlled pre-transplant; and active substance use or dependence (including current tobacco/vaping/marijuana/IV use) without convincing evidence of risk-reduction behaviors unless urgent transplant timelines justify conditional acceptance.

    Evaluation requirements: Pre-transplant evaluation must document donor HLA match/source, transfusion dependence for thalassemia when applicable, the planned conditioning regimen (standard myeloablative regimen for thalassemia), and absence of listed absolute contraindications.

    Clinical documentation must demonstrate all listed medical necessity criteria are met.

    Contraindications

    Absolute contraindications include the following: inability to adhere to the regimen necessary to preserve the transplant, even with caregiver support; infections with highly virulent and/or resistant microbes that are poorly controlled pre-transplant; and active substance use or dependence (including current tobacco use, vaping, nonprescribed marijuana, or IV drug use) without convincing evidence of risk-reduction behaviors unless urgent transplant timelines justify conditional acceptance with a commitment to risk-reduction.

    Pre-Transplant Evaluation Requirements

    Documentation Required

    Evaluation must document donor/source, transfusion status, and conditioning plan

    Pre-transplant evaluation documentation must include donor HLA match and source, evidence of transfusion dependence for thalassemia where required, the planned conditioning regimen (standard myeloablative when specified), and documentation that listed absolute contraindications are absent.

    • Donor HLA match/source (cord blood, bone marrow, or peripheral blood as specified)
    • Transfusion dependence documentation for thalassemia candidates
    • Planned conditioning regimen description

    Transplant Center Requirements

    Note

    No FACT-accreditation or minimum volume requirements stated here

    The policy does not list explicit FACT-accreditation or volume requirements for transplant centers in this document portion; providers should follow any separate plan- or state-specific center requirements.

    Post-Transplant Coverage

    Post‑transplant billing — S2150 (HCPCS)
    HCPCS code referencedS2150
    Global bundling descriptionS2150 describes bone marrow or blood‑derived stem cells (peripheral or umbilical), harvesting, transplantation, and related complications; includes pheresis and cell preparation/storage; marrow ablative therapy; drugs, supplies, hospitalization with outpatient follow‑up; and the number of days of pre‑ and posttransplant care in the global definition.
    Scope of included servicesIncludes inpatient and outpatient transplant‑related services, medical/surgical, diagnostic, emergency, and rehabilitative services as part of the global definition

    Background

    Sickle cell anemia and B-thalassemia are monogenic hemoglobinopathies that cause structural or quantitative defects in hemoglobin, leading to hemolytic anemia, vaso-occlusion, progressive organ damage, and reduced quality of life. Hematopoietic cell transplantation (HCT) is recognized as the only curative therapy for sickle cell disease and is a potential curative option for transfusion-dependent homozygous B-thalassemia; outcomes and candidacy depend on disease features (for example, history of stroke or transfusion dependence), donor availability, and transplant-related risks. Data suggest younger recipients have better outcomes following HCT.

    Definitions

    Definition — Hematopoietic cell transplantation (HCT)
    Definition of HCTProcedure to replace diseased hematopoietic cells with donor‑derived hematopoietic stem cells; recognized as the only cure for sickle cell disease
    Therapeutic intentEstablishes complete donor‑derived erythropoiesis to stabilize organ function (e.g., CNS, lungs) but limited by risks such as graft‑versus‑host disease, rejection, and donor availability
    Key morbiditiesAssociated morbidities include organ toxicities, graft‑versus‑host disease, infertility, and gonadal failure
    Definition — Allogeneic hematopoietic cell transplantation (HCT)
    Allogeneic HCT as curative therapyAllogeneic hematopoietic stem cell transplant is presented as a potential curative therapy for sickle cell disease and transfusion‑dependent beta‑thalassemia
    Donor preference and limitations
    Policy Summary
    PayerCentene
    PolicyAllogeneic Hematopoietic Cell Transplants for Sickle Cell Anemia and B-Thalassemia
    Policy CodePolicy CPMP.108
    Change TypeRevised criteria languageadded cross-references
    Effective Date
    Next Review Date
    Key ActionObtain prior authorization and supply documentation showing medical necessity criteria (donor/source, conditioning regimen, transfusion dependence, and absence of contraindications) are met.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Related MetricsProvider Actions and RequirementsCandidate Selection CriteriaContraindicationsPre-Transplant Evaluation RequirementsTransplant Center RequirementsPost-Transplant CoverageBackgroundDefinitions
    Step Therapy

    Step therapy not described

    No step therapy requirements are described in this policy for allogeneic hematopoietic cell transplantation for sickle cell anemia or homozygous B-thalassemia.

    Note

    Operational highlights and recent revisions

    Note operational updates from the policy: age limit and certain donor-source restrictions were removed and criteria verbiage was reformatted; providers should follow the current criteria language when preparing authorization requests.

    • Removed age limit related to stroke risk and removed first-degree relative donor requirement for cord blood
    • Policy language and notes were reformatted during the latest annual review
    Documentation Required

    Clinical criteria must be documented for indicated diagnosis

    Documentation submitted for authorization must demonstrate that all listed medical necessity criteria for the specific indication (sickle cell anemia or homozygous B-thalassemia) are met, including donor match/source, planned conditioning regimen, transfusion dependence where specified, and absence of absolute contraindications.

    • Evidence of HLA-matched donor or specified stem cell source per indication
    • Planned use of a standard myeloablative conditioning regimen when required
    • Clinical history demonstrating the listed disease-specific criteria (e.g., prior stroke, recurrent acute chest syndrome, transfusion dependence)
    Note

    Policy developed by licensed clinicians; not a payment guarantee

    This clinical policy was developed by appropriately experienced and licensed health care professionals based on literature, guidelines, and specialist review; it does not guarantee payment and coverage remains subject to the member's benefit documents and applicable administrative policies.

    • Coverage decisions are subject to evidence of coverage, policy terms, exclusions, and limitations
    • Health plan may change or withdraw the clinical policy; check plan-level administrative policies
    Denial Risk

    Unsupported transplant types/indications risk denial

    Requests for autologous HCT for sickle cell anemia or B-thalassemia outside the context of gene therapy, and allogeneic HCT for indications other than those specified in this policy, are considered unsupported and risk denial.

    • Autologous HCT for these conditions is considered insufficient evidence unless performed in the context of gene therapy
    • Allogeneic HCT requests for other indications than those listed in policy are not supported
    Note

    Follow state Medicaid and Medicare coverage rules when applicable

    When state Medicaid coverage provisions conflict with this clinical policy, state Medicaid provisions take precedence; for Medicare members, review and apply all applicable NCDs, LCDs, and Medicare Coverage Articles.

    • Refer to the state Medicaid manual for Medicaid enrollee coverage rules
    • Refer to CMS website and applicable Medicare coverage determinations for Medicare members
    Fully matched sibling donors are preferable due to lower risk of graft‑versus‑host disease; donor availability remains a major limitation
    Evidence baseMultiple reports and guideline references document outcomes and support use in selected patients (see cited literature).